M
Michele Mayo
Researcher at AstraZeneca
Publications - 24
Citations - 1010
Michele Mayo is an academic researcher from AstraZeneca. The author has contributed to research in topics: Maytansinoid & Ibrutinib. The author has an hindex of 12, co-authored 24 publications receiving 889 citations. Previous affiliations of Michele Mayo include ImmunoGen, Inc..
Papers
More filters
Journal ArticleDOI
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Yelena Kovtun,Charlene Audette,Michele Mayo,Gregory E. Jones,Heather Doherty,Erin K. Maloney,Hans K. Erickson,Xiuxia Sun,Sharon D. Wilhelm,Olga Ab,Katharine C. Lai,Wayne C. Widdison,Brenda Kellogg,Holly A. Johnson,Jan Pinkas,Robert J. Lutz,Rajeeva Singh,Victor S. Goldmacher,Ravi V. J. Chari +18 more
TL;DR: This study points the way to the development of ADCs that bypass multidrug resistance by conjugating highly cytotoxic maytansinoid DM1 to antibodies via the maleimidyl-based hydrophilic linker PEG(4)Mal to evade the MDR1-mediated resistance.
Journal ArticleDOI
Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates
Hans K. Erickson,Wayne C. Widdison,Michele Mayo,Kathleen R. Whiteman,Charlene Audette,Sharon D. Wilhelm,Rajeeva Singh +6 more
TL;DR: The lipophilic metabolites of the disulfide-linked conjugates were found to be nearly 1000 times more cytotoxic than the more hydrophilic lysine-N(epsilon)-linker-maytansinoids in cell-based viability assays when added extracellularly.
Journal ArticleDOI
Design of Antibody−Maytansinoid Conjugates Allows for Efficient Detoxification via Liver Metabolism
Xiuxia Sun,Wayne C. Widdison,Michele Mayo,Sharon D. Wilhelm,Barbara A. Leece,Ravi V. J. Chari,Rajeeva Singh,Hans K. Erickson +7 more
TL;DR: It is suggested that liver plays an important role in the detoxification of both cleavable and uncleavable AMCs.
Journal ArticleDOI
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
Jutta Deckert,Peter U. Park,Sharon Chicklas,Yong Yi,Min Li,Katharine C. Lai,Michele Mayo,Christina N. Carrigan,Hans K. Erickson,Jan Pinkas,Robert J. Lutz,Thomas Chittenden,John M. Lambert +12 more
TL;DR: A novel anti-CD37 antibody is identified, K7153A, with potent in vitro activity against B-cell lines through multiple mechanisms including apoptosis induction, antibody-dependent cellular cytotoxicity, antibodies to promote phagocytosis and complement-dependent cytotoxic activity.
Journal ArticleDOI
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Tabea Erdmann,Pavel Klener,Pavel Klener,James T. Lynch,Michael Grau,Petra Vockova,Petra Vockova,Jan Molinsky,Jan Molinsky,Diana Tuskova,Diana Tuskova,Kevin Hudson,Urszula M. Polanska,Michael Grondine,Michele Mayo,Beiying Dai,Matthias Pfeifer,Kristian Erdmann,Daniela Schwammbach,Myroslav Zapukhlyak,Annette M. Staiger,Annette M. Staiger,German Ott,Wolfgang E. Berdel,Barry R. Davies,Francisco Cruzalegui,Marek Trneny,Marek Trneny,Peter Lenz,Simon T. Barry,Georg Lenz +30 more
TL;DR: The data suggest that patients should be stratified according to their oncogenic dependencies when treated with PI3K and AKT inhibitors when treating DLBCLs irrespective of their molecular subtype.